A special section in this issue includes four reports on a diverse national sample of nearly 1,500 individuals with schizophrenia—enrollees in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). In the first article, Miranda H. Chakos, M.D., and her colleagues report that the rate of antipsychotic polypharmacy (prescription of two antipsychotics) was relatively low at 5 percent. Rates of concomitant use of antidepressants and mood stabilizers, however, raise questions, because evidence for the effectiveness of adjunctive use of these agents in schizophrenia is mixed or absent (page 1094). In the second article, Lydia A. Chwastiak, M.D., M.P.H., and coauthors report that more than half of 1,424 enrollees (58 percent) had at least one comorbid medical condition and that severity of schizophrenia symptoms was not associated with the number of comorbid illnesses (page 1102). Marvin S. Swartz, M.D., and colleagues found that of the 1,460 enrollees 37 percent had a substance use disorder. Compared with abstinent enrollees, those with substance use and substance use disorder, unless they used cocaine, generally had higher levels of psychosocial functioning (page 1110). In the final article, Deborah A. Perlick, Ph.D., and colleagues report appreciable and varied family burden among 623 family caregivers of enrollees who were interviewed. Demographic characteristics, especially age, and symptom severity accounted for the most burden; perceived patient helpfulness was a moderating factor (page 1117). Robert A. Rosenheck, M.D., who served as guest editor, and coauthors introduce the section (page 1093). In a commentary on page 1075, Jeffrey A. Lieberman, M.D., discusses the fears raised in September 2005 by the publication of early CATIE findings.